BARD1 Life Sciences Ltd
ASX:BD1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
BARD1 Life Sciences Ltd
Cash
BARD1 Life Sciences Ltd
Cash Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
BARD1 Life Sciences Ltd
ASX:BD1
|
Cash
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Sonic Healthcare Ltd
ASX:SHL
|
Cash
AU$557.1m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
8%
|
|
|
Integral Diagnostics Ltd
ASX:IDX
|
Cash
AU$34.1m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
Australian Clinical Labs Ltd
ASX:ACL
|
Cash
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Apiam Animal Health Ltd
ASX:AHX
|
Cash
AU$2.5m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
H
|
Healius Ltd
ASX:HLS
|
Cash
AU$51.6m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-2%
|
|
BARD1 Life Sciences Ltd
Glance View
BARD1 Life Sciences Ltd. is a biotechnology company, which engages in the provision of medical services. The firm is engaged in research, development, and commercialization of non-invasive diagnostic products for the early detection of cancer. The Company’s technologies include BARD1, SubB2, NET and hTERT. BARD1 is a biomarker platform covering various tumor markers including nucleic acids, proteins, and autoantibodies for early cancer diagnosis.SubB2M is a pan-cancer probe for monitoring cancer treatment response and recurrence across a wide range of cancers. NET is designed to capture and purify biomarkers, including acids, cells, and exosomes. hTERT is an antibody-based assay to detect hTERT, a component of telomerase, in cells.
